This compound is primarily utilized in pharmaceutical research and development, particularly in the synthesis of active pharmaceutical ingredients (APIs). It serves as a key intermediate in the creation of compounds targeting neurological and psychiatric disorders, such as depression and anxiety, due to its structural compatibility with receptors in the central nervous system. Additionally, it is employed in the development of small molecule inhibitors for enzyme studies, aiding in the discovery of new therapeutic agents. Its trifluoromethyl group enhances binding affinity and metabolic stability, making it valuable in drug design.